Pharma: Clinic Roundup
Tuesday, September 25, 2012
Boehringer Ingelheim GmbH, of Ingelheim, Germany, said recruitment was completed for two randomized Phase III trials assessing the efficacy and safety of nintedanib (formerly BIBF 1120) 150 mg twice daily in idiopathic pulmonary fibrosis (IPF).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.